Mometasone furoate nasal spray effectively treated ear and palate itching in participants with seasonal allergic rhinitis, according to study results. The 15-day study pooled data from four phase 3, ...

SEATTLE — GSP301, a nasal spray containing a fixed-dose combination of olopatadine hydrochloride/mometasone furoate, is a safe and effective treatment for reducing ...

November 29, 2010 (Phoenix, Arizona) — Once-daily mometasone furoate nasal spray relieves nighttime and early morning nasal congestion in patients with seasonal allergic rhinitis, according to a post ...

This article is part of The Clinical Advisor’s conference coverage from the American Academy of Allergy, Asthma & Immunology in Orlando, Florida. Our staff will report on medical research related to ...

Schering-Plough reported that the FDA has approved a new scent-free formulation of Nasonex prescription nasal inhaled steroid. Nasonex remains the first and only once-daily prescription nasal inhaled ...

Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ryaltris combines olopatadine hydrochloride and ...

Acute rhinosinusitis is a common disease with an increasing incidence rate. It causes substantial costs to the individual and to society through healthcare consumption and absence from work. The use ...

The FDA’s Division of Drug Marketing, Advertising and Communications has issued untitled letters of violation to Schering-Plough for its Nasonex nasal spray, and to GlaxoSmithKline for its Flonase ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...